Company profile for Scancell

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Scancell's primary focus is to develop innovative immunotherapies for cancer that stimulate the body’s own immune system. A key challenge in the fight against cancer is that many tumours successfully evade the body’s own natural defences. Scancell’s mission is to overcome this by developing products that stimulate the immune system to treat or prevent cancer. The field of immuno-oncology is now established as a signific...
Scancell's primary focus is to develop innovative immunotherapies for cancer that stimulate the body’s own immune system. A key challenge in the fight against cancer is that many tumours successfully evade the body’s own natural defences. Scancell’s mission is to overcome this by developing products that stimulate the immune system to treat or prevent cancer. The field of immuno-oncology is now established as a significant weapon in the war against cancer, driven largely by the approval of immune checkpoint inhibitors. However, checkpoint inhibitors alone are not effective in most patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
John Eccles House, Robert Robinson Avenue, Oxford, Science Park, Oxford OX4 4G...
Telephone
Telephone
+44 (0) 1865 338 069
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/09/3202069/0/en/Scancell-updated-Phase-2-data-shows-continued-improvement-in-progression-free-survival-with-iSCIB1-in-patients-with-first-line-advanced-melanoma.html

GLOBENEWSWIRE
09 Dec 2025
Research Update
Research Update

07 Nov 2025

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2025/11/07/3183379/0/en/Research-Update.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/09/11/3148321/0/en/Scancell-reports-Business-Update-and-Financial-Results-for-the-Year-Ended-30-April-2025.html

GLOBENEWSWIRE
11 Sep 2025

https://www.fiercebiotech.com/biotech/scancell-picks-winner-phase-2-cancer-vaccine-face-choosing-next-gen-prospect-pivotal-trial

FIERCE BIOTECH
23 Jul 2025

https://www.fiercebiotech.com/biotech/genmab-buys-second-anti-glycan-antibody-scancell-bringing-total-tab-over-1-billion

FIERCE BIOTECH
04 Dec 2024

https://www.businesswire.com/news/home/20230928299663/en

BUSINESSWIRE
28 Sep 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty